

No. KISS 003/2022

1 February 2022

Subject: Notification of the Investment in Hibiocy Co., Ltd.

To President
Stock Exchange of Thailand

Rojukiss International Public Company Limited (“Company”) would like to notify that the Board of Directors’ Meeting No. 1/2022, held on 28 January 2022 has passed a resolution to approve the Company to invest in Hibiocy Company Limited (“HIB”). The Company already signed Letter of Intent to invest in HIB on 1 February 2022 with the details of investment summarized as below.

The Company will invest in the purchase of new shares in HIB with the amount of Baht 5,200,000 to get proportion of more than 50% shares. Total paid-up capital after this investment will be Baht 10,210,000 which is 102,100 ordinary shares with a par value of Baht 100 per share. The new shareholders’ structure is as follows:

Shareholders	No. of shares	% share
1. Rojukiss International Public Company Limited	52,000	50.9%
2. Ms. Jiraporn Runglerdkriangkrai	25,500	25.0%
3. Mrs. Paporn Prasitdumrong	24,600	24.1%
Total	102,100	100%

After capital increasing, there will be 3 directors which are:

- 1) Mrs. Worawan Chaikamnerd Representative from the Company
- 2) Mr. Anotai Adulbhan Representative from the Company
- 3) Mrs. Paporn Prasitdumrong Representative from existing shareholders

Source of fund for this investment is from the Company’s working capital. HIB’s capital increase transaction is expected to be completed within 28 February 2022 and expected to have revenue from sales from Q3/2022 onwards.

The objective of the investment in HIB is to leverage the expertise and legitimate right in transferring of knowledge to research, develop and commercialize in serving both locally and internationally of medical innovation decoded from antibody technology for SARS-CoV-2 prevention led by renowned World Class

researcher and medical experts from Chulalongkorn University. This new-to-the-world innovation has scientifically proven in preventing or inhibiting Covid-19 virus (as per Memorandum of Understanding in Transferring Technology Knowledge).

By this, KISS has viewed this investment as a key milestone in accelerating our capability to the next level especially for leading innovation of health which is in line with our corporate vision and mission – be the forefront player in both health and beauty innovations of Asia. Lastly, KISS eagerly and proudly intent to be a part of driving technology and innovation led by Thai researchers & medical experts.

HIB is not a connected person of the Company, therefore, the investment in HIB is not the connected transaction in accordance with the Notification of Capital Market Supervisory Board No. TorChor. 21/2551.

The size of this investment in HIB is 0.44% of the total value of consideration paid of the Company as of 30 September 2021. Therefore, this acquisition of the assets shall not require mandatory public disclosure under the Notification of Capital Market Supervisory Board No. TorChor. 20/2551 Re: Rules on Entering into Material Transactions Deemed as Acquisition or Disposal of Assets and Notification of the Board of Governors of the Stock Exchange of Thailand Re: Disclosure of Information and Other Acts of Listed Companies Concerning the Acquisition and Disposition of Assets B.E. 2547. [However, such transaction is an investment in a subsidiary of the Company, therefore, the Company would like to disclose the information to the Stock Exchange of Thailand \(SET\) accordingly.](#)

The Board of Directors considered and agreed that this investment is appropriate and benefits to the Company.

Please be informed accordingly.

Yours sincerely,

(Mrs. Worrawan Chaikamnerd)

Chief Executive Officer